Revance Therapeutics (NASDAQ:RVNC)‘s stock had its “neutral” rating restated by analysts at Guggenheim in a report released on Thursday. They presently have a $42.00 price target on the biopharmaceutical company’s stock. Guggenheim’s target price indicates a potential upside of 27.08% from the company’s previous close.

Several other analysts have also commented on RVNC. Cantor Fitzgerald set a $50.00 price target on shares of Revance Therapeutics and gave the company a “buy” rating in a research report on Thursday, January 4th. Barclays set a $40.00 price target on shares of Revance Therapeutics and gave the company a “buy” rating in a research report on Tuesday, December 19th. SunTrust Banks increased their price target on shares of Revance Therapeutics to $53.00 and gave the company a “buy” rating in a research report on Friday, December 8th. Mizuho increased their price target on shares of Revance Therapeutics from $37.00 to $54.00 and gave the company a “buy” rating in a research report on Wednesday, December 6th. Finally, Piper Jaffray Companies increased their price target on shares of Revance Therapeutics from $28.00 to $51.00 and gave the company an “overweight” rating in a research report on Tuesday, December 5th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have assigned a buy rating to the stock. Revance Therapeutics presently has a consensus rating of “Buy” and an average price target of $43.33.

Shares of Revance Therapeutics (NASDAQ:RVNC) traded down $0.15 on Thursday, reaching $33.05. 53,013 shares of the company’s stock traded hands, compared to its average volume of 906,497. Revance Therapeutics has a one year low of $18.00 and a one year high of $37.45. The firm has a market capitalization of $1,020.00, a price-to-earnings ratio of -8.67 and a beta of 1.62.

Revance Therapeutics (NASDAQ:RVNC) last issued its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.95) by ($0.06). Revance Therapeutics had a negative return on equity of 67.85% and a negative net margin of 37,161.00%. The company had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.05 million. During the same quarter in the previous year, the company posted ($0.64) earnings per share. The company’s quarterly revenue was up .0% compared to the same quarter last year. analysts expect that Revance Therapeutics will post -3.73 EPS for the current fiscal year.

In other news, Director Mark J. Foley acquired 20,000 shares of Revance Therapeutics stock in a transaction that occurred on Tuesday, November 7th. The shares were acquired at an average price of $26.96 per share, with a total value of $539,200.00. Following the completion of the purchase, the director now owns 6,000 shares of the company’s stock, valued at approximately $161,760. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Lauren P. Silvernail sold 11,164 shares of the company’s stock in a transaction that occurred on Thursday, October 12th. The shares were sold at an average price of $26.67, for a total transaction of $297,743.88. The disclosure for this sale can be found here. Insiders sold 36,426 shares of company stock worth $956,026 over the last quarter. Company insiders own 18.86% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Ameriprise Financial Inc. lifted its stake in shares of Revance Therapeutics by 1.0% during the second quarter. Ameriprise Financial Inc. now owns 22,904 shares of the biopharmaceutical company’s stock valued at $604,000 after buying an additional 225 shares during the period. Legal & General Group Plc lifted its stake in shares of Revance Therapeutics by 8.1% during the second quarter. Legal & General Group Plc now owns 5,815 shares of the biopharmaceutical company’s stock valued at $152,000 after buying an additional 438 shares during the period. The Manufacturers Life Insurance Company lifted its stake in shares of Revance Therapeutics by 7.5% during the second quarter. The Manufacturers Life Insurance Company now owns 18,304 shares of the biopharmaceutical company’s stock valued at $483,000 after buying an additional 1,275 shares during the period. Parametric Portfolio Associates LLC lifted its stake in shares of Revance Therapeutics by 6.2% during the second quarter. Parametric Portfolio Associates LLC now owns 29,112 shares of the biopharmaceutical company’s stock valued at $769,000 after buying an additional 1,711 shares during the period. Finally, Rhumbline Advisers lifted its stake in shares of Revance Therapeutics by 10.4% during the second quarter. Rhumbline Advisers now owns 25,333 shares of the biopharmaceutical company’s stock valued at $669,000 after buying an additional 2,395 shares during the period. 76.69% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “Guggenheim Reaffirms Neutral Rating for Revance Therapeutics (RVNC)” was first posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://www.watchlistnews.com/revance-therapeutics-rvnc-rating-reiterated-by-guggenheim/1796489.html.

About Revance Therapeutics

Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.

Analyst Recommendations for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.